2023年1月26日,

风险资本新闻|私人股本风险资本目录|私人股本目录风险资本公司列表/风险资本和私人股本公司和出版来源自1998年以来,VCPro数据库是最可靠的、最新的和负担得起的风险资本目录2023新版本现在可用!(2023年1月更新)VCPro数据库2023 26日版-一个可下载的和可搜索的数据库风险资本与风险资本和私人股本公司6900 +。最可靠的、最新的和负担得起的风险资本的目录。VCPro数据库可以在Windows和macOS版本。自1998年以来,它已经出版。精密神经科学提出4100万美元建造和规模的下一代治疗神经系统疾病的脑机接口公司提出了行业计划微创,可逆的植入。纽约,2023年1月25日,精密神经科学公司,唯一的脑机接口(BCI)公司开发设计为高分辨率的植入物,微创,B系列和可逆的,今天宣布了一项4100万美元资金由Forepont Capital Partners。Mubadala首都德雷伯同事、校友企业和re.Mind资本也参加了一轮,与现有投资者Steadview资本和资本集团。新融资使精度继续招聘顶尖人才,同时为进一步的产品开发和铺平了道路FDA监管审查,预计在未来几个月内。最新的投资使公司总资金5300万美元在两年。 “We imagine a world where devastating neurological conditions – stroke, traumatic brain injury, dementia – are finally treatable,” Michael Mager, CEO of Precision Neuroscience, said. “To reach this world, brain–computer interface technology needs to progress out of the lab and into the clinic. Precision is excited to take on that challenge.” According to the American Neurological Association, nearly 100 million people in the U.S. alone suffer from neurological conditions ranging from migraines to Parkinson’s disease. Precision develops life-changing implants designed to restore neurological function for these individuals. Precision’s implant, the Layer 7 Cortical Interface, is a strip of flexible, thin film material – similar to a piece of Scotch tape, but with a thickness that is 1/5th that of a human hair. It is configured to conform to the surface of the brain without damaging tissue, and can be implanted using a proprietary, minimally invasive cranial micro-slit technique. Precision’s device is the only BCI implant that is engineered to be safely removable. Unlike other minimally invasive approaches, it can process large amounts of data; each microelectrode array comprises 1,024 electrodes, with electrode density 600 times greater than standard cortical arrays. The company holds more than 25 patents and pending patents on its innovative technology. The brain–computer interface industry is undergoing a period of active growth and development, touched off by crucial advances in microfabrication, machine learning, and microelectronics. Co-founded in 2021 by neurosurgeon Ben Rapoport, Precision has assembled some of the top talent in the field. Within two years of the company’s founding, the team has already validated its high-resolution brain–computer interface system and is advancing towards clinical trials in 2023. “Forepont is proud to lead Precision Neuroscience’s Series B raise to support the advancement of Precision’s cutting-edge technology,” Eric Attias, founder and managing partner of Forepont Capital Partners, said. “Precision is pioneering a BCI product that we believe will achieve patient outcomes that were previously thought to be impossible.” About Precision Neuroscience: Precision Neuroscience’s goal is to provide breakthrough treatments for the one billion people worldwide suffering from neurological illnesses. We are building the only brain–computer interface that is designed to be minimally invasive, safely removable, and capable of processing large amounts of data. To learn more about how Precision is connecting human intelligence and artificial intelligence, visit www.precisionneuro.io. Contact: